TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
-3.89%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$50.2M
AUM Growth
+$50.2M
(-62%)
Cap. Flow
-$67.7M
Cap. Flow
% of AUM
-135.02%
Top 10 Holdings %
Top 10 Hldgs %
89.95%
Holding
33
New
–
Increased
2
Reduced
11
Closed
16
Top Buys
| 1 |
Becton Dickinson
BDX
|
$2.59M |
| 2 |
AngioDynamics
ANGO
|
$73.1K |
Top Sells
| 1 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
$6.5M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$6.5M |
| 3 |
Viatris
VTRS
|
$5.67M |
| 4 |
Tenet Healthcare
THC
|
$4.94M |
| 5 |
Abbott
ABT
|
$4.91M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$12.3B
| $6.66M | 4.31% |
675,000
-575,000
| -46% | -$5.67M |
|
|
2
Becton Dickinson
BDX
$55.3B
| $6.46M | 4.19% |
25,000
+10,000
| +67% | +$2.59M |
|
|
MDRX
3
DELISTED
Veradigm Inc. Common Stock
MDRX
| $5.72M | 3.7% |
435,000
-495,000
| -53% | -$6.5M |
|
4
McKesson
MCK
$85.4B
| $4.78M | 3.1% |
11,000
-3,000
| -21% | -$1.3M |
|
|
STRM
5
DELISTED
Streamline Health Solutions
STRM
| $4.77M | 3.09% |
4,930,882
| – | – |
|
6
Collegium Pharmaceutical
COLL
$1.22B
| $4.13M | 2.68% |
185,000
-190,000
| -51% | -$4.25M |
|
7
Phreesia
PHR
$1.88B
| $4.02M | 2.6% |
215,000
-75,000
| -26% | -$1.4M |
|
|
8
AngioDynamics
ANGO
$417M
| $3.47M | 2.25% |
475,000
+10,000
| +2% | +$73.1K |
|
9
Tactile Systems Technology
TCMD
$297M
| $3.36M | 2.18% |
239,222
-60,778
| -20% | -$854K |
|
10
AtriCure
ATRC
$1.84B
| $1.75M | 1.13% |
40,000
-45,000
| -53% | -$1.97M |
|
11
Sanofi
SNY
$121B
| $1.61M | 1.04% |
30,000
-65,000
| -68% | -$3.49M |
|
|
12
Tenet Healthcare
THC
$16.3B
| $1.32M | 0.85% |
20,000
-75,000
| -79% | -$4.94M |
|
13
SI-BONE Inc
SIBN
$719M
| $1.06M | 0.69% |
50,000
-150,000
| -75% | -$3.19M |
|
14
Cerus
CERS
$251M
| $1.05M | 0.68% |
650,000
-1,100,000
| -63% | -$1.78M |
|
|
15
Abbott
ABT
$231B
| – | – |
-45,000
| Closed | -$4.91M |
|
16
Alkermes
ALKS
$4.78B
| – | – |
-100,000
| Closed | -$3.13M |
|
17
Bio-Rad Laboratories Class A
BIO
$8.06B
| – | – |
-2,000
| Closed | -$758K |
|
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| – | – |
-75,000
| Closed | -$6.5M |
|
19
DocGo
DCGO
$153M
| – | – |
-135,000
| Closed | -$1.26M |
|
20
DexCom
DXCM
$29.5B
| – | – |
-16,000
| Closed | -$2.06M |
|
21
InMode
INMD
$944M
| – | – |
-75,000
| Closed | -$2.8M |
|
22
Ironwood Pharmaceuticals
IRWD
$214M
| – | – |
-225,000
| Closed | -$2.39M |
|
|
SLGC
23
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| – | – |
-110,000
| Closed | -$254K |
|
24
Kenvue
KVUE
$39.7B
| – | – |
-1,000
| Closed | -$26.4K |
|
25
iShares S&P 100 ETF
OEF
$22B
| – | – |
0
| – | – |
|